Suppr超能文献

他汀类药物治疗十年后,心血管疾病(CVD)发生率的降低是否有足够的增强效果来证明继续治疗的合理性?

Is there sufficient enhancement of the reduction in CVD rates after a decade of statin therapy to justify continuation?

作者信息

Soverow Jonathan, Watson Karol

机构信息

Division of Cardiology, UCLA Medical Center, 100 UCLA Medical Plaza, Los Angeles, CA, 90095, USA,

出版信息

Curr Atheroscler Rep. 2014 Aug;16(8):432. doi: 10.1007/s11883-014-0432-2.

Abstract

Randomized, controlled clinical trials have shown significant benefits of statin therapy in patients with or at risk for atherosclerotic cardiovascular disease (ASCVD). But these trials typically enroll patients for only 5 years or so, prompting some clinicians to ask what the longer term follow-up of these patients will show. While most trials have a duration of only approximately 5 years, four large trials report extended post-trial follow-up to 10 years, and these trials, as well as multiple large cohort studies, suggest an expected benefit of statins' effects beyond 10 years. In this review we will summarize the current state of the literature, the benefits noted to date, and the potentially accumulating, adverse effects of long-term statin use.

摘要

随机对照临床试验表明,他汀类药物治疗对患有动脉粥样硬化性心血管疾病(ASCVD)或有风险的患者有显著益处。但这些试验通常仅让患者入组约5年,这促使一些临床医生询问这些患者的长期随访结果会如何。虽然大多数试验的持续时间仅约为5年,但四项大型试验报告了试验后长达10年的随访情况,这些试验以及多项大型队列研究表明,他汀类药物的效果预计在10年后仍有益处。在本综述中,我们将总结当前的文献状况、迄今所指出的益处以及长期使用他汀类药物可能累积的不良反应。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验